Retatrutide half-life & pharmacokinetics

Reported half-life

Approximately 144 hours (~6 days) plasma half-life through fatty-acid acylation supporting albumin binding. Similar dosing interval expectations to tirzepatide (once weekly) and semaglutide (once weekly). Phase III TRIUMPH programme is testing once-weekly subcutaneous administration.

The half-life and pharmacokinetic profile of Retatrutide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (Phase III clinical trial route; not licensed)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Triple GLP-1R / GIPR / glucagon receptor agonist; Phase III clinical-development unlicensed compound.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Retatrutide acts as follows:

Retatrutide (Eli Lilly development code LY3437943) is a synthetic triple-agonist peptide engineered to activate three distinct receptors in the incretin and counter-regulatory pathways: the glucagon-like peptide-1 receptor (GLP-1R, addressed by semaglutide), the glucose-dependent insulinotropic polypeptide receptor (GIPR, added by tirzepatide as the dual agonist), and the glucagon receptor — adding a third pharmacological dimension absent from earlier-generation incretin compounds. The triple-agonist concept extends the additive-receptor hypothesis from dual-agonist (tirzepatide) success: if GLP-1R + GIPR combination produces greater weight loss than GLP-1R alone, perhaps GLP-1R + GIPR + glucagon-R combination produces greater weight loss still.

See the full Retatrutide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.